This paper was presented at the EORTC-NCI-AACR meeting last week. The poster shows data on NOTCH expression in cell lines and evaluated the effects of NOCH inhibition.

1. Abstract # 98
o Notch pathway is involved in
cell differentiation, proliferation,
apoptosis, angiogenesis, drug
resistance, and epithelial-to-
mesenchymal transition
o Notch pathway activation leads
to a proteolytic cleavage,
releasing the Notch intracellular
domain (NICD), which
translocates to the nucleus
o NICD translocation triggers the
activation of target genes, such
as HES1
Introduction
To characterize the basal
activation and the role of
Notch4 in a panel of human
cancer cell lines
Aim of the study
Western Blot: A panel of 8 pancreatic (PDAC), 8
Head & Neck (H&N), 5 cholangiocarcinoma
(CK), and 5 colorectal (CRC) human cancer cell
lines were characterized for their basal
expression of Notch4 intracellular domain
(NICD4), HES1, Vimentin, and E-cadherin. The
expression of NUMB, a protein involved in NICD
proteasomal degradation, was assessed in 2 cell
lines per tumor type, one with low Notch4
activation and one with high Notch4 activation
Proliferation assay: Proliferation was assessed
by MTT each day from day 0 to day 5
Migration test: Migration was assessed by
wound-healing assay. Pictures were done after
4h, 24h, and 48h
Antiproliferative assay with PF-03084014:
MTT assays were used to study the
antiproliferative effects of PF-03084014, a Notch
inhibitor, after 72h exposure to 8 different
concentrations
Effects of PF-03084014 on cell signaling:
Effects of Notch inhibition on cell signaling was
assessed by western blot after 24- and 48- hours
exposure to 20µM of PF-03084014 in the two
selected H&N cell lines
Statistic: All data on proliferation are mean ±
SEM
Material and Methods
Results
Contact:
lastorgues@afr-oncology.com
Conclusions
o High Notch4 basal activation is correlated with increased proliferation and migration in a large panel of human cancer types, as well as higher
sensitivity of tumor cells to PF-03084014, a Notch inhibitor
o PF-03084014 inhibits Notch signaling pathway in the high-sensitive H&N cell and activates AKT survival pathway in the low-sensitive one
o Since Notch inhibition is currently an interesting topic for antitumor therapy, this study could help to
select tumor types that could be good candidate for Notch inhibition in the clinic
Involvement of Notch signaling pathway in a panel of human cancer cell lines
Notch4 is activated in most of the cancer cell lines, and is correlated with
high vimentin expression in PDAC cells
Lucile Astorgues-Xerri1, Mathieu Martinet1, Eric Raymond2, Sandrine Faivre3, Annemilaï Tijeras-Raballand1
1AFR Oncology, Lariboisière Hospital, Paris, France ; 2Saint Joseph Paris Hospital, Medical Oncology Department, Paris, France; 3Beaujon University Hospital, Medical Oncology Department, Clichy France
30th EORTC/AACR/NCI symposium
Dublin (13-16 November)
Cell lines characterization
Involvement of Notch4 basal activation in proliferation and migration
Effect of the Notch inhibitor PF-03084014
Effects on cell signaling
NUMB is overexpressed in all low Notch4
activated cells, suggesting a correlation
between low Notch4 activation and
proteasomal degradation
Notch4 basal activation is associated with an increased proliferation and migration in all cancer types
PF-03084014 was more effective in cell lines with high Notch4
activation than in cell lines with low Notch4 activation
Cell lines TU8988S TU8988T FaDu Hep2 SNU1196 HuCCT1 NCI-H508 HCT116
IC50, µM
(95% CI)
82,9
(50,8-135)
59,8
(32,7-109)
86,2
(60,2-123)
40,4
(28,2-57,9)
250,1
(wide)
41,4
(37,4-45,8)
> 300 ~ 90
Antiproliferative effects
24- and 48-h exposure
to 20µM PF-03084014:
Protein expression
• inhibits HES1
(strongest
effect in Hep2)
• increases pAKT
(strongest
effect in FaDu)